ILF/CIPHER Thematic Roundtable on Paediatric HIV Diagnostics: Early Infant Diagnosis and Beyond
Sunday, 19 July 2015, 09:00 – 14:00 PST / Room 306, Vancouver Convention Centre, Vancouver, Canada

CONCEPT NOTE

The Industry Liaison Forum (ILF) and the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER, the IAS Paediatric HIV Programme) are pleased to welcome you to the thematic roundtable on Paediatric HIV Diagnostics: Early Infant Diagnosis and Beyond.

From development to implementation, there are many challenges in paediatric HIV diagnostics. Indeed, although the 2013 WHO guidelines recommended testing infants at risk of perinatal HIV infection between 4-6 weeks by virological testing, there are discussions around testing at birth to ensure that treatment can start as soon as possible, especially before mortality peaks around three months. Beyond testing at birth and the PMTCT cascade, the diagnostics needs of infants and children will require integration in other healthcare platforms. As children age into adolescence and transition into adulthood, diagnostics will remain essential and, for treatment-experienced infected children, viral load monitoring and genotyping will become more important. It is hoped that this thematic roundtable will cover these and other issues bridging the industry, programming, regulatory and normative guidance spheres.

This meeting will start by looking at the paediatric diagnostics continuum, from development to implementation, highlighting challenges along the way and existing initiatives. An overview of WHO guidance as well as insights working-up to the next revision of the 2013 Consolidated Guidelines will also be provided. The bulk of the time available will be for a group discussion on creative solutions to overcome barriers to development and delivery of optimal paediatric HIV diagnostics.

The main objectives for this meeting are to:

• Inform attendees from different backgrounds about challenges along the diagnostics development and implementation continuum
• Raise awareness of the existing initiatives in paediatric HIV diagnostics and how they fit together
• Provide background data on the clinical, normative and policy contexts of paediatric HIV diagnostics
• Highlight opportunities and potential synergies
• Catalyze collaboration among attendees from different types of organizations.

Thank you for your interest.

Sébastien Morin
Research Officer, Industry Liaison Forum
International AIDS Society, Switzerland

Marissa Vicari
Manager, CIPHER
International AIDS Society, Switzerland
About the Collaborative Initiative for Paediatric HIV Education and Research

CIPHER is aimed at optimizing clinical management and delivery of services to infants, children and adolescents affected by HIV in resource-limited settings through advocacy and research promotion. CIPHER was launched as a two-year research initiative in 2012 with the generous support of an unrestricted grant from ViiV Healthcare’s Paediatric Innovation Seed Fund. Over the first two years, a core programme of activities was developed, including a grant programme, a global paediatric HIV cohort collaboration and online paediatric HIV cohort database. By the end of 2013, the IAS reaffirmed its commitment to paediatric HIV by making paediatrics a programme priority, with CIPHER as the official branding. Thanks to renewed support from founding sponsor ViiV Healthcare and now with support from Janssen as well, CIPHER will continue to build on the activities developed in the initial phase and expand its scope with an advocacy and outreach component. More information is available on the CIPHER website (www.iasociety.org/cipher).

About the Industry Liaison Forum

The ILF is a mechanism to constructively engage all stakeholders (industry and others) on issues in line with IAS Member Priorities. It is designed to take advantage of the IAS’s key strengths: its well-respected convening power; its acknowledged independence from industry and other key partners and stakeholders; and its diverse working groups composed of some of the world’s top thought leaders and scientific experts in a wide array of fields. This work is guided by a strong, multi-stakeholder advisory group; it aims to enhance the impact of the global response to HIV and related co-morbidities. More information is available on the ILF website (www.iasociety.org/ilf).

The ILF is grateful for the unrestricted support received from its Gold Partners (Gilead Sciences, MSD and ViiV Healthcare), its Silver Partners (AbbVie, Alere and Janssen) and its Bronze Partners (Abbott, Cipla, Female Health Company, Omega Diagnostics, Roche Molecular Systems and Sysmex Corporation). The ILF Thematic Roundtable Series is sponsored by ILF Gold and Silver Partners.